Skip to main content

Advertisement

SpringerLink
Log in

Gender Differences in Ischemic Cardiomyopathy

  • Women and Ischemic Heart Disease (A. Maran, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Cardiovascular disease remains the leading cause of death among women globally, majority of which are due to ischemic heart disease. Despite the recent advances in the overall management of CVD, there are unique challenges in the diagnosis and management of women as well as poorer outcomes.

Recent Findings

Women with ischemic cardiomyopathy experience significant morbidity and mortality. Differences in underlying pathology, delays in presentation, diagnosis, and treatment as well as the under-representation of women in clinical trials contribute to these poor outcomes.

Summary

In this review, we discuss the nuances of gender-specific differences in the burden, clinical presentation, and outcomes of ischemic cardiomyopathy in women, in addition to discussion of areas needing further research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603. https://doi.org/10.1161/CIR.0000000000000485.

    Article  PubMed  PubMed Central  Google Scholar 

  2. •• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803. https://doi.org/10.1016/j.jacc.2017.04.025. Recent heart failure guidelines with update on newer therapies.

    Article  PubMed  Google Scholar 

  3. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72.

    Article  PubMed  Google Scholar 

  4. •• McSweeney JC, Rosenfeld AG, Abel WM, Braun LT, Burke LE, Daugherty SL, et al. Preventing and experiencing ischemic heart disease as a woman: state of the science: a scientific statement from the American Heart Association. Circulation. 2016;133(13):1302–31. https://doi.org/10.1161/CIR.0000000000000381. Scientific statement from the American Heart Association highlighting the prevention of IHD in women.

    Article  PubMed  PubMed Central  Google Scholar 

  5. •• Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, et al. Acute mocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016;133(9):916–47. https://doi.org/10.1161/CIR.0000000000000351. Scientific statement from the American Heart Association highlighting the presentation, treatment and outcomes of acute MI in women.

    Article  CAS  PubMed  Google Scholar 

  6. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–59. https://doi.org/10.1161/CIRCRESAHA.113.300268.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, et al. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol. 2013;61(14):1510–7. https://doi.org/10.1016/j.jacc.2013.01.022.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.

    Article  PubMed  Google Scholar 

  9. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89(2):157–61.

    Article  CAS  PubMed  Google Scholar 

  10. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288(1):49–57.

    Article  PubMed  Google Scholar 

  11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

    Article  CAS  PubMed  Google Scholar 

  12. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37. https://doi.org/10.1056/NEJMoa062462.

    Article  CAS  PubMed  Google Scholar 

  13. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52. https://doi.org/10.1016/S0140-6736(04)17018-9.

    Article  PubMed  Google Scholar 

  14. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161(14):1717–23.

    Article  CAS  PubMed  Google Scholar 

  15. Barrett-Connor E. The Rancho Bernardo Study: 40 years studying why women have less heart disease than men and how diabetes modifies women’s usual cardiac protection. Glob Heart. 2013;8(2). https://doi.org/10.1016/j.gheart.2012.12.002.

    Article  Google Scholar 

  16. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45. https://doi.org/10.1161/01.cir.0000437738.63853.7a.

    Article  PubMed  Google Scholar 

  17. Bittner V, Johnson BD, Zineh I, Rogers WJ, Vido D, Marroquin OC, et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women’s ischemia syndrome evaluation (WISE). Am Heart J. 2009;157(3):548–55. https://doi.org/10.1016/j.ahj.2008.11.014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Victor BM, Teal V, Ahedor L, Karalis DG. Gender differences in achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol. 2014;113(10):1611–5. https://doi.org/10.1016/j.amjcard.2014.02.018.

    Article  CAS  PubMed  Google Scholar 

  19. Kim JK, Alley D, Seeman T, Karlamangla A, Crimmins E. Recent changes in cardiovascular risk factors among women and men. J Women’s Health (Larchmt). 2006;15(6):734–46. https://doi.org/10.1089/jwh.2006.15.734.

    Article  Google Scholar 

  20. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996–1002.

    Article  CAS  PubMed  Google Scholar 

  21. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391–7.

    Article  PubMed  Google Scholar 

  22. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145(5):408–15.

    Article  CAS  PubMed  Google Scholar 

  23. Rich-Edwards JW, Fraser A, Lawlor DA, Catov JM. Pregnancy characteristics and women’s future cardiovascular health: an underused opportunity to improve women’s health? Epidemiol Rev. 2014;36:57–70. https://doi.org/10.1093/epirev/mxt006.

    Article  PubMed  Google Scholar 

  24. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women’s ischemia syndrome evaluation. J Clin Endocrinol Metab. 2008;93(4):1276–84. https://doi.org/10.1210/jc.2007-0425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol. 2009;53(3):221–31. https://doi.org/10.1016/j.jacc.2008.09.042.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Xu X, Bao H, Strait K, Spertus JA, Lichtman JH, D'Onofrio G, et al. Sex differences in perceived stress and early recovery in young and middle-aged patients with acute myocardial infarction. Circulation. 2015;131(7):614–23. https://doi.org/10.1161/CIRCULATIONAHA.114.012826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–66. https://doi.org/10.1161/CIR.0000000000000556.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I, Almeida-Gonzalez C, Catalan-Serra P, Montserrat JM. Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study. Ann Intern Med. 2012;156(2):115–22. https://doi.org/10.7326/0003-4819-156-2-201201170-00006.

    Article  PubMed  Google Scholar 

  29. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322. https://doi.org/10.1161/CIR.0000000000000152.

    Article  PubMed  Google Scholar 

  30. •• Lichtman JH, Leifheit EC, Safdar B, Bao H, Krumholz HM, Lorenze NP, et al. Sex differences in the presentation and perception of symptoms among young patients with myocardial infarction: evidence from the VIRGO study (variation in recovery: role of gender on outcomes of young AMI patients). Circulation. 2018;137(8):781–90. https://doi.org/10.1161/CIRCULATIONAHA.117.031650. Recent study that identified sex specific differences in patients presenting with MI.

    Article  PubMed  PubMed Central  Google Scholar 

  31. • McSweeney J, Cleves MA, Fischer EP, Moser DK, Wei J, Pettey C, et al. Predicting coronary heart disease events in women: a longitudinal cohort study. J Cardiovasc Nurs. 2014;29(6):482–92. https://doi.org/10.1097/JCN.0b013e3182a409cc. A gender specific study that identifies a predictive screen for coronary heart disease events in women.

    Article  PubMed  PubMed Central  Google Scholar 

  32. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;127(4):e362–425. https://doi.org/10.1161/CIR.0b013e3182742cf6.

    Article  PubMed  Google Scholar 

  33. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164. https://doi.org/10.1016/j.jacc.2012.07.013.

    Article  PubMed  Google Scholar 

  34. Dickerson JA, Nagaraja HN, Raman SV. Gender-related differences in coronary artery dimensions: a volumetric analysis. Clin Cardiol. 2010;33(2):E44–9. https://doi.org/10.1002/clc.20509.

    Article  PubMed  Google Scholar 

  35. Vaccarino V, Badimon L, Corti R, de Wit C, Dorobantu M, Hall A, et al. Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. Cardiovasc Res. 2011;90(1):9–17. https://doi.org/10.1093/cvr/cvq394.

    Article  CAS  PubMed  Google Scholar 

  36. Bell JR, Mellor KM, Wollermann AC, Delbridge LM. Cardiac ischaemic stress: cardiomyocyte Ca(2)(+), sex and sex steroids. Clin Exp Pharmacol Physiol. 2011;38(10):717–23. https://doi.org/10.1111/j.1440-1681.2011.05567.x.

    Article  CAS  PubMed  Google Scholar 

  37. Sharaf B, Wood T, Shaw L, Johnson BD, Kelsey S, Anderson RD, et al. Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. Am Heart J. 2013;166(1):134–41. https://doi.org/10.1016/j.ahj.2013.04.002.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Dreyer RP, Sciria C, Spatz ES, Safdar B, D'Onofrio G, Krumholz HM. Young women with acute myocardial infarction: current perspectives. Circ Cardiovasc Qual Outcomes. 2017;10(2). https://doi.org/10.1161/CIRCOUTCOMES.116.003480.

    Google Scholar 

  39. Alfonso F, Paulo M, Lennie V, Dutary J, Bernardo E, Jimenez-Quevedo P, et al. Spontaneous coronary artery dissection: long-term follow-up of a large series of patients prospectively managed with a “conservative” therapeutic strategy. JACC Cardiovasc Interv. 2012;5(10):1062–70. https://doi.org/10.1016/j.jcin.2012.06.014.

    Article  PubMed  Google Scholar 

  40. • Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and No Obstructive Coronary Artery Disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation. 2017;135(11):1075–92. https://doi.org/10.1161/CIRCULATIONAHA.116.024534. Recent publication highlighting the current understanding and future research ideas for INOCA.

    Article  PubMed  Google Scholar 

  41. Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55(25):2825–32. https://doi.org/10.1016/j.jacc.2010.01.054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Taqueti VR, Shaw LJ, Cook NR, Murthy VL, Shah NR, Foster CR, et al. Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease. Circulation. 2017;135(6):566–77. https://doi.org/10.1161/CIRCULATIONAHA.116.023266.

    Article  PubMed  Google Scholar 

  43. Sanghavi M, Gulati M. Sex differences in the pathophysiology, treatment, and outcomes in IHD. Curr Atheroscler Rep. 2015;17(6):511. https://doi.org/10.1007/s11883-015-0511-z.

    Article  CAS  PubMed  Google Scholar 

  44. Ostadal B, Ostadal P. Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. Br J Pharmacol. 2014;171(3):541–54. https://doi.org/10.1111/bph.12270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Dunlay SM, Roger VL. Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure. Curr Heart Fail Rep. 2012;9(4):267–76. https://doi.org/10.1007/s11897-012-0107-7.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Cavasin MA, Tao Z, Menon S, Yang XP. Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sci. 2004;75(18):2181–92. https://doi.org/10.1016/j.lfs.2004.04.024.

    Article  CAS  PubMed  Google Scholar 

  47. Crabbe DL, Dipla K, Ambati S, Zafeiridis A, Gaughan JP, Houser SR, et al. Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol. 2003;41(2):300–6.

    Article  PubMed  Google Scholar 

  48. Dreyer RP, Dharmarajan K, Kennedy KF, Jones PG, Vaccarino V, Murugiah K, et al. Sex differences in 1-year all-cause rehospitalization in patients after acute myocardial infarction: a prospective observational study. Circulation. 2017;135(6):521–31. https://doi.org/10.1161/CIRCULATIONAHA.116.024993.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Gupta A, Wang Y, Spertus JA, Geda M, Lorenze N, Nkonde-Price C, et al. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol. 2014;64(4):337–45. https://doi.org/10.1016/j.jacc.2014.04.054.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Rosen SE, Henry S, Bond R, Pearte C, Mieres JH. Sex-specific disparities in risk factors for coronary heart disease. Curr Atheroscler Rep. 2015;17(8):49. https://doi.org/10.1007/s11883-015-0523-8.

    Article  PubMed  Google Scholar 

  51. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;130(25):e344–426. https://doi.org/10.1161/CIR.0000000000000134.

    Article  PubMed  Google Scholar 

  52. D’Onofrio G, Safdar B, Lichtman JH, Strait KM, Dreyer RP, Geda M, et al. Sex differences in reperfusion in young patients with ST-segment-elevation myocardial infarction: results from the VIRGO study. Circulation. 2015;131(15):1324–32. https://doi.org/10.1161/CIRCULATIONAHA.114.012293.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wu AH, Parsons L, Every NR, Bates ER. Second National Registry of myocardial I. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002;40(8):1389–94.

    Article  PubMed  Google Scholar 

  54. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109(4):494–9. https://doi.org/10.1161/01.CIR.0000109691.16944.DA.

    Article  PubMed  Google Scholar 

  55. Radovanovic D, Erne P, Urban P, Bertel O, Rickli H, Gaspoz JM, et al. Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry. Heart. 2007;93(11):1369–75. https://doi.org/10.1136/hrt.2006.106781.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, et al. Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK. J Am Coll Cardiol. 2000;36(3 Suppl A):1063–70.

    Article  CAS  PubMed  Google Scholar 

  57. Lansky AJ, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging. 2012;5(3 Suppl):S62–72. https://doi.org/10.1016/j.jcmg.2012.02.003.

    Article  PubMed  Google Scholar 

  58. Wong SC, Sleeper LA, Monrad ES, Menegus MA, Palazzo A, Dzavik V, et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK trial registry. J Am Coll Cardiol. 2001;38(5):1395–401.

    Article  CAS  PubMed  Google Scholar 

  59. Jeger RV, Urban P, Harkness SM, Tseng CH, Stauffer JC, Lejemtel TH, et al. Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: a pooled analysis of trials. Acute Card Care. 2011;13(1):14–20. https://doi.org/10.3109/17482941.2010.538696.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J. 2008;29(6):748–56. https://doi.org/10.1093/eurheartj/ehn062.

    Article  PubMed  Google Scholar 

  61. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, et al. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(3 Suppl):S21–9. https://doi.org/10.1016/j.jacc.2004.12.084.

    Article  PubMed  Google Scholar 

  62. Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation. 2008;117(14):1787–801. https://doi.org/10.1161/CIRCULATIONAHA.107.726562.

    Article  PubMed  Google Scholar 

  63. Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010;122(6):597–602. https://doi.org/10.1161/CIRCULATIONAHA.110.940619.

    Article  PubMed  Google Scholar 

  64. Ni H, Coady S, Rosamond W, Folsom AR, Chambless L, Russell SD, et al. Trends from 1987 to 2004 in sudden death due to coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Am Heart J. 2009;157(1):46–52. https://doi.org/10.1016/j.ahj.2008.08.016.

    Article  PubMed  Google Scholar 

  65. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104(18):2158–63.

    Article  CAS  PubMed  Google Scholar 

  66. Koopman C, Vaartjes I, Heintjes EM, Spiering W, van Dis I, Herings RM, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. Eur Heart J. 2013;34(41):3198–205. https://doi.org/10.1093/eurheartj/eht368.

    Article  CAS  PubMed  Google Scholar 

  67. Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol. 2003;42(12):2128–34.

    Article  PubMed  Google Scholar 

  68. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–8. https://doi.org/10.1056/NEJM200105313442201.

    Article  CAS  PubMed  Google Scholar 

  69. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the cardiac insufficiency Bisoprolol study (CIBIS II). Circulation. 2001;103(3):375–80.

    Article  CAS  PubMed  Google Scholar 

  70. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC, Group M-HS. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF). Circulation. 2002;105(13):1585–91.

    Article  CAS  PubMed  Google Scholar 

  71. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13. https://doi.org/10.1016/S0140-6736(03)13800-7.

    Article  CAS  PubMed  Google Scholar 

  72. Group CTS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35. https://doi.org/10.1056/NEJM198706043162301.

    Article  Google Scholar 

  73. Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302. https://doi.org/10.1056/NEJM199108013250501.

    Article  Google Scholar 

  74. Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–91. https://doi.org/10.1056/NEJM199209033271003.

    Article  Google Scholar 

  75. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the losartan heart failure survival study ELITE II. Lancet. 2000;355(9215):1582–7.

    Article  CAS  PubMed  Google Scholar 

  76. Cohn JN, Tognoni G. Valsartan heart failure trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667–75. https://doi.org/10.1056/NEJMoa010713.

    Article  CAS  PubMed  Google Scholar 

  77. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618–26. https://doi.org/10.1161/01.CIR.0000146819.43235.A9.

    Article  CAS  PubMed  Google Scholar 

  78. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N Engl J Med. 1986;314(24):1547–52. https://doi.org/10.1056/NEJM198606123142404.

    Article  CAS  PubMed  Google Scholar 

  79. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–10. https://doi.org/10.1056/NEJM199108013250502.

    Article  CAS  PubMed  Google Scholar 

  80. Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, et al. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol. 2006;48(11):2263–7. https://doi.org/10.1016/j.jacc.2006.06.020.

    Article  PubMed  Google Scholar 

  81. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33(7):1948–55.

    Article  CAS  PubMed  Google Scholar 

  82. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–17. https://doi.org/10.1056/NEJM199909023411001.

    Article  CAS  PubMed  Google Scholar 

  83. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. https://doi.org/10.1056/NEJMoa030207.

    Article  CAS  PubMed  Google Scholar 

  84. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. https://doi.org/10.1056/NEJMoa1009492.

    Article  CAS  PubMed  Google Scholar 

  85. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255.

    Article  CAS  PubMed  Google Scholar 

  86. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85. https://doi.org/10.1016/S0140-6736(10)61198-1.

    Article  CAS  PubMed  Google Scholar 

  87. Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33. https://doi.org/10.1056/NEJM199702203360801.

    Article  Google Scholar 

  88. Zareba W, Moss AJ, Jackson Hall W, Wilber DJ, Ruskin JN, McNitt S, et al. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol. 2005;16(12):1265–70. https://doi.org/10.1111/j.1540-8167.2005.00224.x.

    Article  PubMed  Google Scholar 

  89. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50. https://doi.org/10.1056/NEJMoa032423.

    Article  CAS  PubMed  Google Scholar 

  90. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37. https://doi.org/10.1056/NEJMoa043399.

    Article  CAS  PubMed  Google Scholar 

  91. Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60. https://doi.org/10.1016/S0140-6736(09)60503-1.

    Article  CAS  Google Scholar 

  92. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation. 2011;123(11):1243–62. https://doi.org/10.1161/CIR.0b013e31820faaf8.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009;54(21):1935–45. https://doi.org/10.1016/j.jacc.2009.05.074.

    Article  CAS  PubMed  Google Scholar 

  94. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15. https://doi.org/10.1056/NEJMoa0706482.

    Article  CAS  PubMed  Google Scholar 

  95. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2014;35(23):1541–50. https://doi.org/10.1093/eurheartj/ehu075.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997;29(5):1074–80.

    Article  CAS  PubMed  Google Scholar 

  97. Long-Term Intervention with Pravastatin in Ischaemic Disease Study G. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–57. https://doi.org/10.1056/NEJM199811053391902.

    Article  Google Scholar 

  98. Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP, Group TS. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011;4(3):328–36. https://doi.org/10.1161/CIRCOUTCOMES.110.957720.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Hsue PY, Bittner VA, Betteridge J, Fayyad R, Laskey R, Wenger NK, et al. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Am J Cardiol. 2015;115(4):447–53. https://doi.org/10.1016/j.amjcard.2014.11.026.

    Article  CAS  PubMed  Google Scholar 

  100. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124(16):1774–82. https://doi.org/10.1161/CIRCULATIONAHA.111.037283.

    Article  PubMed  Google Scholar 

  101. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med. 1996;334(21):1349–55. https://doi.org/10.1056/NEJM199605233342101.

    Article  CAS  PubMed  Google Scholar 

  102. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41(9):1529–38.

    Article  CAS  PubMed  Google Scholar 

  103. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327(10):678–84. https://doi.org/10.1056/NEJM199209033271002.

    Article  CAS  PubMed  Google Scholar 

  104. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA. 1995;273(18):1450–6.

    Article  CAS  PubMed  Google Scholar 

  105. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet. 2000;355(9215):1575–81.

    CAS  Google Scholar 

  106. Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, et al. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol. 2002;40(4):693–702.

    Article  CAS  PubMed  Google Scholar 

  107. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058–68. https://doi.org/10.1056/NEJMoa042739.

    Article  CAS  PubMed  Google Scholar 

  108. Dickstein K, Kjekshus J, Group OSCotOS. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet. 2002;360(9335):752–60.

    Article  CAS  PubMed  Google Scholar 

  109. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906. https://doi.org/10.1056/NEJMoa032292.

    Article  CAS  PubMed  Google Scholar 

  110. • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077. This study newly recognized the role of ARNIs in heart failure, adding a new class of drug to HF therapies.

    Article  CAS  PubMed  Google Scholar 

  111. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347(18):1403–11. https://doi.org/10.1056/NEJMoa021266.

    Article  CAS  PubMed  Google Scholar 

  112. Adams KF Jr, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46(3):497–504. https://doi.org/10.1016/j.jacc.2005.02.091.

    Article  CAS  PubMed  Google Scholar 

  113. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49. https://doi.org/10.1056/NEJMoa050496.

    Article  CAS  PubMed  Google Scholar 

  114. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) trial. J Am Coll Cardiol. 2011;57(7):813–20. https://doi.org/10.1016/j.jacc.2010.06.061.

    Article  PubMed  Google Scholar 

  115. Woo GW, Petersen-Stejskal S, Johnson JW, Conti JB, Aranda JA Jr, Curtis AB. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J Interv Card Electrophysiol. 2005;12(2):107–13. https://doi.org/10.1007/s10840-005-6545-3.

    Article  PubMed  Google Scholar 

  116. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298(13):1525–32. https://doi.org/10.1001/jama.298.13.1525.

    Article  CAS  PubMed  Google Scholar 

  117. Russo AM, Stamato NJ, Lehmann MH, Hafley GE, Lee KL, Pieper K, et al. Influence of gender on arrhythmia characteristics and outcome in the multicenter UnSustained tachycardia trial. J Cardiovasc Electrophysiol. 2004;15(9):993–8. https://doi.org/10.1046/j.1540-8167.2004.04050.x.

    Article  PubMed  Google Scholar 

  118. Mehta NK, Abraham WT, Maytin M. ICD and CRT use in ischemic heart disease in women. Curr Atheroscler Rep. 2015;17(6):512. https://doi.org/10.1007/s11883-015-0512-y.

    Article  PubMed  Google Scholar 

  119. Hess PL, Hernandez AF, Bhatt DL, Hellkamp AS, Yancy CW, Schwamm LH, et al. Sex and race/ethnicity differences in implantable cardioverter-defibrillator counseling and use among patients hospitalized with heart failure: findings from the get with the guidelines-heart failure program. Circ Heart Fail. 2017;10(6). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003635.

    Google Scholar 

  120. Santangeli P, Pelargonio G, Dello Russo A, Casella M, Bisceglia C, Bartoletti S, et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm. 2010;7(7):876–82. https://doi.org/10.1016/j.hrthm.2010.03.042.

    Article  PubMed  Google Scholar 

  121. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385–95. https://doi.org/10.1056/NEJMoa1009540.

    Article  CAS  PubMed  Google Scholar 

  122. Rho RW, Patton KK, Poole JE, Cleland JG, Shadman R, Anand I, et al. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Circulation. 2012;126(20):2402–7. https://doi.org/10.1161/CIRCULATIONAHA.111.069245.

    Article  PubMed  Google Scholar 

  123. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157–87. https://doi.org/10.1016/j.healun.2012.09.013.

    Article  PubMed  Google Scholar 

  124. Bogaev RC, Pamboukian SV, Moore SA, Chen L, John R, Boyle AJ, et al. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. J Heart Lung Transplant. 2011;30(5):515–22. https://doi.org/10.1016/j.healun.2010.12.009.

    Article  PubMed  Google Scholar 

  125. Birks EJ, McGee EC Jr, Aaronson KD, Boyce S, Cotts WG, Najjar SS, et al. An examination of survival by sex and race in the HeartWare Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE) Bridge to Transplant (BTT) and continued access protocol trials. J Heart Lung Transplant. 2015;34(6):815–24. https://doi.org/10.1016/j.healun.2014.12.011.

    Article  PubMed  Google Scholar 

  126. • Magnussen C, Bernhardt AM, Ojeda FM, Wagner FM, Gummert J, de By T, et al. Gender differences and outcomes in left ventricular assist device support: the European registry for patients with mechanical circulatory support. J Heart Lung Transplant. 2018;37(1):61–70. https://doi.org/10.1016/j.healun.2017.06.016. This recent study highlights poorer outcomes of women with LVADs.

    Article  PubMed  Google Scholar 

  127. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation Report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1037–46. https://doi.org/10.1016/j.healun.2017.07.019.

    Article  PubMed  Google Scholar 

  128. • Hsich EM, Blackstone EH, Thuita L, McNamara DM, Rogers JG, Ishwaran H et al. Sex differences in mortality based on united network for organ sharing status while awaiting heart transplantation. Circ Heart Fail. 2017;10(6). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003635.This recent study highlights the poorer outcomes women experience on the heart transplant waitlist.

  129. Grupper A, Nestorovic EM, Daly RC, Milic NM, Joyce LD, Stulak JM, et al. Sex related differences in the risk of antibody-mediated rejection and subsequent allograft vasculopathy post-heart transplantation: a single-center experience. Transplant Direct. 2016;2(10):e106. https://doi.org/10.1097/TXD.0000000000000616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report--2011. J Heart Lung Transplant. 2011;30(10):1078–94. https://doi.org/10.1016/j.healun.2011.08.003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, Medical University of South Carolina (MUSC), Strom Thurmond Gazes Building, 30 Courtenay Drive, BM 212, MSC 592, Charleston, SC, 29425, USA

    Laura Divoky, Anbukarasi Maran & Bhavadharini Ramu

Authors
  1. Laura Divoky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anbukarasi Maran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bhavadharini Ramu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhavadharini Ramu.

Ethics declarations

Conflict of Interest

Laura Divoky, Anbukarasi Maran, and Bhavadharini Ramu declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Women and Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Divoky, L., Maran, A. & Ramu, B. Gender Differences in Ischemic Cardiomyopathy. Curr Atheroscler Rep 20, 50 (2018). https://doi.org/10.1007/s11883-018-0750-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-018-0750-x

Keywords

Search

Navigation